Enlivex Ltd.
ENLVNasdaq
$4.68
↓ -1.5%Jul 17 close · end-of-day
Price
1Y↓ -74.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$227.0M
Enterprise Value
$225.1M
P/E
0.2
P/S
—
P/B
11.9
EV/EBITDA
—
PEG
—
FCF Yield
-4.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$1.2B
Free Cash Flow (TTM)
-$10.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
6484.4%
ROIC
-66.9%
Debt / Equity
—
Net Cash
$1.9M
Return 1Y
-74.0%
Company profile
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state.
- CEO
- Oren Hershkovitz
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Website
- enlivex.com
Earnings
ENLV Q2 2025 Earnings
Period ends 2025-06-30
MetricActualYoY
Revenue——
Diluted EPS-$0.08↓ -50.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.8M | -$19.3M | -$25.8M | -$29.4M | -$15.9M | -$15.0M |
| Net income | -$11.8M | -$14.5M | -$31.1M | -$29.1M | -$15.0M | $1.2B |
| Diluted EPS | -$0.90 | -$0.81 | -$1.69 | -$1.56 | -$0.73 | $25.48 |
| Operating cash flow | -$11.0M | -$17.5M | -$24.0M | -$23.5M | -$13.0M | -$10.4M |
| Free cash flow | -$12.0M | -$19.2M | -$32.1M | -$23.8M | -$13.1M | -$10.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '22 | Q2 '22 | Q2 '23 | Q2 '23 | Q2 '24 | Q2 '24 | Q2 '25 | Q2 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | -$5.9M | — | -$6.6M | — | -$3.0M | — | -$3.1M |
| Net income | -$8.2M | -$9.9M | -$7.2M | -$6.8M | -$4.1M | -$3.1M | -$3.5M | -$1.9M |
| Diluted EPS | — | -$0.54 | — | -$0.37 | — | -$0.16 | — | -$0.08 |
| Operating cash flow | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 13, 2026
May 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.